21 November 2017 - Cardiovascular disease is the leading cause of death for people with T2D, who are at a 2 – 4 times higher risk of cardiovascular disease than the general population.

Novo Nordisk announced today that Health Canada has approved a product monograph update for Victoza (liraglutide). Victoza is now approved to reduce the incidence of cardiovascular (CV) death in patients with type 2 diabetes mellitus and established cardiovascular disease when added to diet, exercise, and the current standard of care therapy.

The product monograph update for Victoza reflects the Canadian Diabetes Association Clinical Practice Guidelines and is supported by results from the LEADER trial, which examined the long-term effects of Victoza in patients with type 2 diabetes and established CVD. In the LEADER trial, Victoza (liraglutide up to 1.8 mg; median daily dose 1.78 mg) statistically significantly reduced the risk of CV death, non-fatal myocardial infarction (heart attack) and non-fatal stroke by 13% versus placebo. The overall risk reduction was derived from a statistically significant 22% reduction in cardiovascular death with Victoza treatment versus placebo and non- significant reductions in non-fatal myocardial infarction and non-fatal stroke.

Read Novo Nordisk press release